Simvastatin-induced apoptosis in osteosarcoma cells: A key role of rhoa-ampk/p38 mapk signaling in antitumor activity

Walied A. Kamel, Eiji Sugihara, Hiroyuki Nobusue, Sayaka Yamaguchi-Iwai, Nobuyuki Onishi, Kenta Maki, Yumi Fukuchi, Koichi Matsuo, Akihiro Muto, Hideyuki Saya, Takatsune Shimizu

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Osteosarcoma is the most common type of primary bone tumor, novel therapeutic agents for which are urgently needed. To identify such agents, we screened a panel of approved drugs with a mouse model of osteosarcoma. The screen identified simvastatin, which inhibited the proliferation and migration of osteosarcoma cells in vitro. Simvastatin also induced apoptosis in osteosarcoma cells in a manner dependent on inhibition of the mevalonate biosynthetic pathway. It also disrupted the function of the small GTPase RhoA and induced activation of AMP-activated protein kinase (AMPK) and p38 MAPK, with AMPK functioning upstream of p38 MAPK. Inhibitors of AMPK or p38 MAPK attenuated the induction of apoptosis by simvastatin, whereas metformin enhanced this effect of simvastatin by further activation of AMPK. Although treatment with simvastatin alone did not inhibit osteosarcoma tumor growth in vivo, its combination with a fat-free diet induced a significant antitumor effect that was enhanced further by metformin administration. Our findings suggest that simvastatin induces apoptosis in osteosarcoma cells via activation of AMPK and p38 MAPK, and that, in combination with other approaches, it holds therapeutic potential for osteosarcoma.

Original languageEnglish
Pages (from-to)182-192
Number of pages11
JournalMolecular Cancer Therapeutics
Volume16
Issue number1
DOIs
Publication statusPublished - 01-2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Simvastatin-induced apoptosis in osteosarcoma cells: A key role of rhoa-ampk/p38 mapk signaling in antitumor activity'. Together they form a unique fingerprint.

  • Cite this

    Kamel, W. A., Sugihara, E., Nobusue, H., Yamaguchi-Iwai, S., Onishi, N., Maki, K., Fukuchi, Y., Matsuo, K., Muto, A., Saya, H., & Shimizu, T. (2017). Simvastatin-induced apoptosis in osteosarcoma cells: A key role of rhoa-ampk/p38 mapk signaling in antitumor activity. Molecular Cancer Therapeutics, 16(1), 182-192. https://doi.org/10.1158/1535-7163.MCT-16-0499